Most candidates for a hantavirus vaccine remain in preclinical or early Phase 1 stages as of October 2026, with no candidates in advanced clinical trials capable of meeting regulatory standards for approval and distribution before year-end. Official monitoring shows limited progress on New World strains like Andes virus despite recent outbreaks, as developers face challenges including the need for multi-dose regimens, surrogate endpoints for efficacy, and low commercial incentives for a rare zoonotic disease. Historical timelines for similar vaccines indicate Phase 2 and 3 trials typically require several years without emergency acceleration. While single-dose mRNA or DNA platforms have shown promise in animal models and early immunogenicity data, realistic shifts would require unexpected regulatory fast-tracking or breakthrough trial results not currently indicated by surveillance updates.